Mavrilimumab is a human
MAB for the treatment of rheumatoid arthritis. It targets the GM-CSF
receptor-alpha. More at: http://en.wikipedia.org/wiki/Mavrilimumab
There have been two
studies on mavrilimumab at the EULAR 2014 Meeting in Paris.
[OP0282]
M. Sleeman and colleagues
presented: “MAVRILIMUMAB REDUCES IL-17A AND IL-17F PRODUCTION IN BIOMAP HUMAN
PRIMARY CELL SYSTEMS MODELING T CELL-DEPENDENT B CELL ACTIVATION”.Conclusions: “In
an in vitro human primary cell model of T cell dependent B cell activation,
mavrilimumab inhibited production of soluble cytokines including IL-17A and
IL-17F that are induced by endogenous release of GMCSF in the system. As TH17 biology
has been implicated in the pathogenesis of RA (Gaffen, 2009) these data suggest
that mavrilimumab could impact IL-17 production from pathogenic T cells in the
rheumatic joint.”
[SAT0260] W. White and
colleagues looked at: “BIOMARKERS ASSOCIATED WITH RHEUMATOID ARTHRITIS DISEASE
ACTIVITY INCLUDING JOINT DAMAGE CORRELATE WITH CHANGES IN CLINICAL RESPONSE IN
SUBJECTS TREATED WITH MAVRILIMUMAB AT DOSES ABOVE 10 MG”.Conclusions: “Promising
results of mavrilimumab support further clinical development at doses greater
than 10 mg. Mechanistically, the drug suppressed both acute phase and
inflammatory blood markers. Tracking of disease activity by MBDA showed a clear
biomarker-based dose-response relationship. The association of MBSD decline
with radiographic damage will be assessed in an on-going phase 2b study.”
Compared to the three
studien presented the the ACR 2013 Meeting in San Diego this is a step
backwards, no matter how interesting the studies themselves might be. Still no
phase 3 study with stressable data on radiographic progression. So it means for us waiting longer to see, if mavrilimumab matured into a usable drug.
Links:
No comments:
Post a Comment